Related Experiment Video
Updated: Aug 16, 2025

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods
Published on: December 21, 2019
Substrate Specificity and Kinetics of RNA Hydrolysis by SARS-CoV-2 NSP10/14 Exonuclease
Tyler L Dangerfield1, Kenneth A Johnson1
1Institute for Cellular and Molecular Biology, Department of Molecular Biosciences, University of Texas, 2500 Speedway, Austin, Texas 78712, United States.
Abstract:
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19, continues to evolve resistance to vaccines and existing antiviral therapies at an alarming rate, increasing the need for new direct-acting antiviral drugs. Despite significant advances in our fundamental understanding of the kinetics and mechanism of viral RNA replication, there are still open questions regarding how the proofreading exonuclease (NSP10/NSP14 complex) contributes to replication fidelity and resistance to nucleoside analogs. Through single turnover kinetic analysis, we show that the preferred substrate for the exonuclease is double-stranded RNA without any mismatches. Double-stranded RNA containing a 3'-terminal remdesivir was hydrolyzed at a rate similar to a correctly base-paired cognate nucleotide. Surprisingly, single-stranded RNA or duplex RNA containing a 3'-terminal mismatch was hydrolyzed at rates 125- and 45-fold slower, respectively, compared to the correctly base-paired double-stranded RNA. These results define the substrate specificity and rate of removal of remdesivir for the exonuclease and outline rigorous kinetic assays that could help in finding next-generation exonuclease inhibitors or nucleoside analogs that are able to evade excision. These results also raise important questions about the role of the polymerase/exonuclease complex in proofreading during viral replication. Addressing these questions through rigorous kinetic analysis will facilitate the search for desperately needed antiviral drugs to combat COVID-19.
Insights
The SARS-CoV-2 exonuclease preferentially removes remdesivir from double-stranded RNA. This finding helps in developing new antiviral drugs against COVID-19 by understanding viral RNA replication and resistance mechanisms.
Area of Science:
- Virology
- Molecular Biology
- Drug Discovery
Background:
- Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is evolving resistance to current therapies.
- New direct-acting antiviral drugs are urgently needed to combat COVID-19.
- The SARS-CoV-2 exonuclease complex (NSP10/NSP14) plays a role in viral RNA replication fidelity and antiviral resistance, but its precise function remains unclear.
Purpose of the Study:
- To investigate the substrate specificity and kinetic properties of the SARS-CoV-2 exonuclease complex.
- To determine the efficiency of remdesivir removal by the exonuclease.
- To inform the development of next-generation antiviral drugs and inhibitors.
Main Methods:
- Single turnover kinetic analysis was employed to study the exonuclease activity.
- The hydrolysis rates of various RNA substrates, including those with mismatches or remdesivir incorporation, were measured.
- Enzyme kinetics were rigorously analyzed to define substrate preferences.
Main Results:
- The SARS-CoV-2 exonuclease preferentially hydrolyzes double-stranded RNA lacking mismatches.
- Remdesivir at the 3'-terminus of double-stranded RNA was hydrolyzed at a rate comparable to a correctly base-paired nucleotide.
- Single-stranded RNA or mismatched duplex RNA were hydrolyzed significantly slower (125- and 45-fold, respectively) than correctly paired double-stranded RNA.
Conclusions:
- The study defines the substrate specificity and remdesivir removal rate for the SARS-CoV-2 exonuclease.
- These findings provide a basis for designing improved exonuclease inhibitors and nucleoside analogs that evade excision.
- Further kinetic analysis is crucial for understanding the polymerase/exonuclease complex's role in viral replication and for developing effective COVID-19 therapeutics.
Related Concept Videos
Ribozymes
Ribozymes can...
Viruses with RNA Genomes

